Clinical implication of therapeutic drug monitoring on voriconazole from the aspect of the analysis for CYP2C19 gene

Japanese Journal of Antibiotics

Volumn 63, Issue 3, 2010, Pages 255-264

  Kimura, Masao ^a   Yamagishi, Yuka ^a   Kawasumi, Noriyo ^a   Hagihara, Mao ^a   Hasegawa, Takaaki ^a   Mikamo, Hiroshige ^a  

^a AICHI MEDICAL UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; VORICONAZOLE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; HUMAN; ILLUSION; JAPANESE; LIVER TOXICITY; PHARMACOGENETICS; SIDE EFFECT; VISUAL ILLUSION;

ADULT; AGED; AGED, 80 AND OVER; ANTIFUNGAL AGENTS; ARYL HYDROCARBON HYDROXYLASES; DRUG MONITORING; FEMALE; HUMANS; LIVER; MALE; MIDDLE AGED; PYRIMIDINES; TRIAZOLES;

EID: 77954394937     PISSN: 03682781     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. GOODWIN, M. L. & R. H. DREW: Antifungal serum concentration monitoring: an update. J. Antimicrob. Chemother. 61: 17-25, 2008
2. PASCUAL, A.; T. CALANDRA, S. BOLAY, et al.: Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46: 201-211, 2008
3. KIMURA, M.; I. IEIRI, K. MAMIYA, et al.: Genetic polymorphism of cytochrome P 450s, CYP2C19, and CYP2C9 in a Japanese population. Ther. Drug Monit. 20: 243-247, 1998
4. SHIMIZU, T.; H. OCHIAI, F. ASELL, et al.: Bioinformatics research on inter-racial difference in drug metabolism I. Analysis on frequencies of mutant alleles and poor metabolizers on CYP2D6 and CYP2C19. Drug Metabo. Pharmacokinet. 18: 48-70, 2003
5. WOOD, N.: Voriconazole 53 (S-2): 16-23, 2005
6. IKEDA, Y.; K. UMEMURA, K. KONDO, et al.: Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status. Clin. Pharmacol. Ther. 75: 587-588, 2004
7. WEISS, J.; M. M. HOEVEL, J. BURHENNE, et al.: CYP2C19 genotype is a major factor contributing to the highly variable pharmacokinetics of voriconazole. J. Clin. Pharmacol. 49: 196-204, 2009
8. WALSH, T. J.; E. J. ANAISSIE, D. W. DENNING, et al.; Infectious Diseases Society of America: Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect Dis. 46: 327-360, 2008
9. KARTHAUS, M.: Voriconazole versus amphotericin B for invasive aspergillosis. N. Eng. J. Med. 347: 2080-2081, 2002
10. HERBRECHT, R.; D. W. DENNING, T. F. PATTERSON, et al.; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group: Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N. Eng. J. Med. 347: 408-415, 2002
11. MURAYAMA, N.; N. IMAI, T. NAKANE, et al.: Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes. Biochem. Pharmacol. 73: 2020-2026, 2007
12. KUBOTA, T.; K. CHIBA, T. ISHIZAKI: Genotyping of S-mephenytoin 4′-hydroxylation in an extended Japanese population. Clin. Pharmacol. Ther. 60: 661-666, 1996
13. FURUTA, T.; K. OHASHI, K. KOSUGE, et al.: CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin. Pharmacol. Ther. 65: 552-561, 1999
14. SMITH, J.; N. SAFDAR, V. KNASINSKI, et al.: Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50: 1570-1572, 2006
15. LEWIS, R. J.: What is the "therapeutic range" for voriconazole. Clin. Infect. Dis. 46: 212-214, 2008
16. BRUGGEMANN, R. J. M.; J. P. DONNELLY, R. E. AARNOUTSE, et al.: Therapeutic drug monitoring of voriconazole. Ther. Drug Monit. 30: 403-411, 2008
17. PURKINS, L.; N. WOOD, P. GHAHRAMANI, et al.: Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46: 2546-2553, 2002
18. TAN, K.; N. BRAYSHAW, K. TOMASZEWSKI, et al.: Investigation of the potential relationship between plasma voriconazole concentration and visual adverse events or liver function test abnormalities. J. Clin. Pharmacol. 46: 235-243, 2006
19. TRIFFO, S.; G. PENNICK, J. PI, et al.: Monitoring plasma voriconazole levels may be necessary to avoid sub-therapeutic levels in hematopoietic stem cell transplant recipients. Cancer 109: 1532-1535, 2007
20. NEELY, M.; T. RUSHING, A. KOVACS, et al.: Voriconazole pharmacokinetics and pharmacodynamics in children. Clin. Infect. Dis. 50: 27-36, 2010